CANbridge Pharmaceuticals Inc. (1228.HK)
HKD 0.16
(0.65%)
HKD 0.16
(0.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -366.54 Million CNY | 23.16% |
| 2022 | -477.04 Million CNY | 57.33% |
| 2021 | -1.11 Billion CNY | -36.11% |
| 2020 | -821.5 Million CNY | -279.78% |
| 2019 | -216.3 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -109.63 Million CNY | 0.0% |
| 2024 Q1 | -109.63 Million CNY | -33.92% |
| 2023 Q3 | -81.86 Million HKD | 19.27% |
| 2023 FY | -366.54 Million CNY | 23.16% |
| 2023 Q2 | -101.4 Million CNY | 0.0% |
| 2023 Q1 | -101.4 Million CNY | 9.3% |
| 2023 Q4 | -81.86 Million CNY | 0.0% |
| 2022 Q2 | -117.17 Million CNY | 0.0% |
| 2022 Q1 | -117.17 Million CNY | 19.04% |
| 2022 FY | -477.04 Million CNY | 57.33% |
| 2022 Q4 | -111.81 Million CNY | 0.0% |
| 2022 Q3 | -111.81 Million CNY | 4.57% |
| 2021 Q1 | -104.1 Million CNY | -38.11% |
| 2021 FY | -1.11 Billion CNY | -36.11% |
| 2021 Q4 | -144.72 Million CNY | 0.0% |
| 2021 Q3 | -144.72 Million CNY | 44.67% |
| 2021 Q2 | -261.58 Million CNY | -151.27% |
| 2020 Q4 | -75.37 Million CNY | 0.0% |
| 2020 Q2 | -51.9 Million CNY | -80.08% |
| 2020 Q3 | -75.37 Million CNY | -45.22% |
| 2020 Q1 | -28.82 Million CNY | 0.0% |
| 2020 FY | -821.5 Million CNY | -279.78% |
| 2019 FY | -216.3 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 640.885% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 140.82% |